The new guidance is...

..."consistent with our view that MAPD [i.e., Medicare Advantage Prescription Drug] plans are well positioned to flexibly aid the administration agenda on bringing negotiated pricing into the reimbursement for Part B drugs."

— Leerink analyst Ana Gupte, writing about the new guidance issued by CMS that will allow Medicare Advantage plans to use step therapy for Part B drugs starting in 2019.